Board
IAN NISBET, PhD
Non Executive Chair- Dr. Ian Nisbet is currently Chief Executive Officer for Xenome Ltd. Ian has more than 2 decades of pharmaceutical industry experience, including roles as CEO of Meditech Research Ltd.; Senior Director, Business Development and Oncology Alliance Management at Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, and more than 17 years at CSL Ltd. Ian was Board Chair for Adipogen Pharmaceuticals Pty Ltd. and currently sits on the Boards of Ambri Ltd. and Velacor Pty Ltd.
ANDREW BAKER, PhD
Non Executive Director- Dr. Andrew Baker is an Associate Director of GBS Venture Partners, Ltd. Andrew has over 18 years experience in the pharmaceutical and biotechnology industries, including 14 years working with Genetech, Bayer and as Deputy Director of Johnson & Johnson Research in Sydney. Andrew was a non-executive director for Adipogen Pharmaceuticals Pty Ltd. and currently sits on the Boards of Cryptopharma Pty ltd., Hatchtech Pty Ltd. and Spinifex Pty Ltd.
MICHAEL A. COWLEY, PhD
Non-Executive Director- Professor. Michael A. Cowley is the Director of the Monash Obesity & Diabetes Institute. Michael is a physiologist and bioentrepreneur with a strong focus on obesity, diabetes, and metabolic disorders with extensive experience in the discovery and development of therapies to treat metabolic diseases and the repurposing of existing medicines as therapies for obesity and diabetes. Prior to Monash Michael was a founder and Chief Scientific Officer of California-based Orexigen® Therapeutics, Inc. (NASDAQ: OREX) and a scientist in the Division of Neuroscience at the Oregon National Primate Research Center of the Oregon Health & Science University. During Michael’s tenure at Orexigen® the company advanced a combination product (Contrave®) to successful phase 3 clinical testing as an obesity therapy. Michael is a Victorian Endowment for Science, Knowledge and Innovation (VESKI) Innovation Fellow and a Pfizer Senior Research Fellow for 2009. He was recently awarded the prestigious Commonwealth Science Minister’s Prize for Life Scientist of the Year.
JOHN KUREK, PhD
Non Executive Director- Dr. John Kurek is the Biotechnology Investment Manager at Uniseed, Australia’s leading early stage venture capital fund. At Uniseed he is responsible for the successful growth and financial management of early stage biotechnology companies, and brings 10 years industry experience as a Biotechnology Manager with a focus on the strategic design and implementation of drug development programs John’s previous roles have included Pharmaceutical Development Manager at BioDiem Ltd, where he was responsible for managing the preclinical, clinical and regulatory aspects of BioDiem’s drug development programs, and Preclinical Development Manager at Amrad Corporation Ltd where he was responsible for the management of preclinical drug development projects. His experience extends from drug discovery, to the phase I-II clinical phases of drug development. John has a PhD in Neuroscience and a Post Graduate Diploma in Drug Evaluation and Pharmaceutical Science, both from the University of Melbourne and is a Graduate of the Australian Institute of Company Directors. John is a Director of Fibrotech Therapeutics Pty Ltd, Spinifex Pharmaceuticals Pty Ltd, Hatchtech Pty Ltd and Radical Biotechnology Pty Ltd.
MATTHEW MORGAN, BCom, BAppSci, MBA, MAICD
Non Executive Director- Mr. Matt Morgan is a private equity manager with Queensland Investment Corporation (QIC). He serves on the boards of CNSBio Inc, XBio Systems Inc and Biocomm Pty Ltd and is the founder of Diversa Ltd: an emerging wealth management Company. Matt is also a Kauffman Fellow and has held a variety of senior management roles in start-up and expansion stage companies both in the UK and Australia.